Clinical Trials Logo

Clinical Trial Summary

This randomized phase I trial studies how well olfactory training works in improving sense of smell after radiation therapy in patients with paranasal sinus or nasopharyngeal cancer. Olfactory training may improve smell function after radiation therapy in patients with paranasal sinus or nasopharyngeal cancer.


Clinical Trial Description

PRIMARY OBJECTIVES:

I. To evaluate the effect of olfactory training on olfactory function in patients with paranasal sinus and nasopharyngeal carcinoma suffering from olfactory loss after radiation.

SECONDARY OBJECTIVES:

I. To evaluate the possible effect of olfactory training on quality of life in patients with paranasal sinus and nasopharyngeal carcinoma suffering from olfactory loss after radiation.

II. To study rate and severity of olfactory dysfunction after radiation therapy in patients with paranasal sinus or nasopharyngeal carcinoma.

III. To evaluate the possible preventive effect of olfactory training on olfactory dysfunction in patients with paranasal sinus and nasopharyngeal carcinoma who will undergo radiation therapy.

OUTLINE: Patients are randomized to 1 of 2 arms. Arm I: Patients undergo olfactory training by smelling 4 essential oils in vials (rose, lemon, clove, and eucalyptus) over 15 seconds each, twice daily for 12 weeks.

Arm II: Patients undergo sham training by smelling canola oil in 4 vials over 15 seconds each, twice daily for 12 weeks. ;


Study Design


Related Conditions & MeSH terms

  • Carcinoma
  • Nasopharyngeal Neoplasms
  • Paranasal Sinus Neoplasms
  • Stage 0 Nasopharyngeal Carcinoma
  • Stage 0 Paranasal Sinus Cancer
  • Stage I Nasopharyngeal Carcinoma
  • Stage I Paranasal Sinus Cancer
  • Stage II Nasopharyngeal Carcinoma
  • Stage II Paranasal Sinus Cancer
  • Stage IIA Nasopharyngeal Carcinoma
  • Stage IIB Nasopharyngeal Carcinoma
  • Stage III Nasopharyngeal Carcinoma
  • Stage III Paranasal Sinus Cancer
  • Stage IV Nasopharyngeal Carcinoma
  • Stage IV Paranasal Sinus Cancer
  • Stage IVA Nasopharyngeal Carcinoma
  • Stage IVA Paranasal Sinus Cancer
  • Stage IVB Nasopharyngeal Carcinoma
  • Stage IVB Paranasal Sinus Cancer
  • Stage IVC Nasopharyngeal Carcinoma
  • Stage IVC Paranasal Sinus Cancer

NCT number NCT03049358
Study type Interventional
Source Stanford University
Contact
Status Terminated
Phase N/A
Start date December 2016
Completion date October 2018

See also
  Status Clinical Trial Phase
Completed NCT02538510 - Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery Phase 1/Phase 2
Completed NCT01616849 - Study of Chemotherapy Combined With Nimotuzumab in Untreated Metastatic Nasopharyngeal Carcinoma Phase 2
Recruiting NCT01655628 - GC Regimen Chemotherapy Plus CIK Cells for Metastatic Nasopharyngeal Carcinoma Phase 2
Withdrawn NCT04231864 - Durvalumab and Epacadostat for Treatment of Unresectable, Recurrent, or Metastatic Epstein-Barr Virus Positive Nasopharyngeal Cancer Phase 2
Recruiting NCT03044743 - PD-1 Knockout EBV-CTLs for Advanced Stage Epstein-Barr Virus (EBV) Associated Malignancies Phase 1/Phase 2